Inside the Formula | The Supplement Company That Publishes Its Own Bad News

With Metagenics & TESTED by SuppCo: Inside the Formula is a new sponsored series featuring brands in the TESTED by SuppCo certification program, where we spotlight the fascinating research behind products that have received the certification. Learn more about TESTED by SuppCo.

Here is something most supplement shoppers never think about: the companies making most daily vitamins probably started with marketing. Metagenics started with science and stumbled into products… almost by accident.

Most supplement brands begin with a product concept, find an ingredient trending on social media or at a trade show, and work backward to justify it. Metagenics inverted that sequence entirely. The company started as a research organization, with mechanisms of action, systems biology, and clinical outcomes as its north star, and the products followed from there. 

That's not a branding claim. It's a founding logic that, after more than 40 years, still shapes how the company decides what to make, what to test, and what to walk away from.

That founding logic matters because it creates a different kind of pressure in the product development process. When you start with research, the first question you ask is not "what will sell?" It's "what does the science actually support?" Every product at Metagenics is preceded by a deep dive into underlying biology: what pathways are involved, what intervention could realistically make a difference, what clinical outcome they're actually striving for. 

The loudest input in that process, by deliberate design, comes not from marketing or leadership but from practicing healthcare practitioners: MD specialists, naturopathic doctors, dieticians, the people seeing patients every day and translating unmet clinical needs back to the development team.

What makes Metagenics unusual isn't just that they conduct rigorous pre-market testing. It's that they publish the results, even when the data doesn't cooperate. The company has put its own formulas through peer-reviewed scientific scrutiny rather than asking consumers and practitioners to operate on trust alone. 

That takes a specific kind of institutional discipline, because publishing your own research means being publicly accountable when results are inconclusive or disappointing. Most supplement companies don't take that risk. Metagenics also runs two-year stability programs on certain finished products, tracking how actives interact with excipients, moisture, oxygen, and light inside the actual dosage form over time, long after most companies have already moved on.

TESTED by SuppCo anonymously purchased Metagenics products the same way any consumer would, off the shelf, no advance notice. Those products were then sent to an ISO-accredited independent laboratory using validated testing methods to verify that what's on the label is actually in the bottle: the correct ingredients, at the stated dosages, meeting the claims made. For a brand built on practitioner trust and peer-reviewed accountability, label accuracy isn't a baseline expectation. That's the whole point. If a practitioner is dosing a patient based on what a label says, that number has to be real.

I sat down with Dr. Malisa Carullo, Senior Manager of Medical Information and Safety at Metagenics, to dive deeper into the science.

JG: "Metagenics has been around for over 40 years. What does that length of time actually mean in practice and how does it shape the way you're building supplements today?"

MC: "Most people don't realize that Metagenics started as a research organization and then stumbled into products. That order of operations shapes everything. The DNA of the company hasn't changed, so when we're developing something today, the question isn't 'what is going to sell.' It's really 'what is the science going to support?' Before formulating even begins, we put a lot of time into understanding patient needs, mechanisms of action, systems biology, and the clinical outcome we're striving for."

JG: "Every ingredient has to pass an evaluation before it gets anywhere near development. What does that actually look like, and what would disqualify something?"

MC: "Every ingredient goes through a really rigorous raw material evaluation before it gets near development: identification, specification, purity and safety testing, microbiology, physical and chemical attributes, batch-to-batch consistency. But beyond that is bioavailability, and that's one of our key pillars. We don't care if an ingredient looks promising on paper. We care whether it can actually be absorbed and act in the body. So we invest in our own pharmacokinetics and bioavailability testing rather than just relying on what the supplier tells us. And then there's dose. An ingredient can be biologically active in theory, but if the effective dose is unrealistic to formulate, it doesn't translate into a usable product."

JG: "You publish your own research on your own formulas and you're accountable to that data even when it doesn't say what you hoped. What happens internally when the results disappoint?"

MC: "Publishing our own formula data signals that we're going to take accountability seriously. We're putting our products through rigorous scientific scrutiny. We're not asking practitioners to just rely on trust. We want to generate the evidence, peer-reviewed, tested in humans on the actual formula. An unexpected or negative result isn't failure. It's information. It shapes the product, the dose, sometimes the underlying hypothesis. The alternative is only publishing what flatters the company. And that's not science. That's fluff."

JG: "You guys track finished products on a shelf for up to two years. Why does stability testing matter that much at that stage?"

MC: "The biggest lesson is that even strong ingredients aren't enough on their own. The matrix they live in is really, really important: how actives interact with each other, with excipients, moisture, oxygen inside the dosage form. We've seen actives that look great analytically at release but perform poorly over time because of subtle pH shifts, oxidation, moisture uptake in the finished product. When products struggle, they rarely fail suddenly. It's a slow, predictable degradation that traces back to a formulation choice or an environmental exposure. Products that hold up over time tend to share three things: the active is inherently stable, the formulation protects it, and the packaging matches how sensitive the active really is."

The Process Behind the Promise: What You'll Never Read on a Label

I'll be honest: I don't walk into these conversations as an easy audience. I have 3 degrees in this space, I've spent years at the intersection of science communication and the supplement industry, and I've heard every quality claim in the book. I know how thin the evidence is behind most of them, and I've developed a pretty finely tuned sensitivity for the gap between what brands say about their standards and what those standards actually look like in practice.

What caught my attention with Metagenics wasn't the tenure or the marketing language. It was the specific texture of how the company handles failure. 

The willingness to publish research on your own formulas when the results are inconvenient is a meaningful signal that many supplement companies would never send. 

It's a form of institutional accountability that is genuinely rare, because it removes the option to quietly shelve a product when the data gets uncomfortable.

The two-year stability programs were an equally notable data point for me. It's one thing to test a product at release. It's another to follow it through heat, humidity, and light exposure over months and years, tracking how the formulation matrix holds up under real-world conditions. Most companies test at the front door and consider their job done. Metagenics is still watching long after that. Whether every product in the portfolio lives up to this process uniformly is something that external verification, not internal assurances, is better positioned to confirm.

What I came away with was a picture of a company where the quality infrastructure is not a marketing layer sitting on top of a standard supplement operation. It appears, at least from this conversation, to be load-bearing. Which is either a genuinely unusual thing to find or one of the most sophisticated talking points in the industry. Watching the full interview is probably the better way to decide which.